1Blad6 J, Rosinol L, Cibeira M T et al. Hematopoietic stem cell trans- plantation for multiple myeloma beyond 2010 [ J ]. Blood, 2010 ; 115 ( 18 ) :3655-3663.
2Di Bemardo A, Macor P, Guamotta C et al. Humoral immunotherapy of multiple myeloma: perspectives and perplexities [ J ]. Expert Opin Biol Ther,2010;10(6) :863-873.
3Ikeda H, Hideshima T, Fulciniti Met al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxici- ty against CD138-positive multiple myeloma ceils in vitro and in vivo [ J]. Clin Cancer Res,2009 ; 15 ( 12 ) :4028-4037.
4Coldmacher V S, Kovtun Y V. Antibody-drug conjugates : using mono- clonal antibodies for delivery of cytotoxic payloads to cancer cells [ J ]. Therapeutic Delivery, 2011 ; 2 ( 3 ) : 397-416.
5Tai Y T, Soydan E, Song Wet al. CS1 promotes multiple myeloma cell adhesion,clonogenic growth, and tumorigenicity via c-maf-mediatedinteractions with bone marrow stroma] ceils [ J]. Blood,2009; 113 (18) :4309-4318.
6Tai Y T,Dillon M,Song Wet al. Anti-CS1 humanized monoclonal an- tibody HuLuc63 inhibits myelorna cell adhesion and induces antibody- dependent cellular cytotoxicity in the bone marrow milieu E J]. Blood, 2008;112(4) :1329-1337.
7Hsi E D, Steinle R, Balasa B et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma [ J]. Clin Cancer Res,2008 ;14(9) :2775-2784.
8van Rhee F,Szmania S M,Dillon Met d. Combinatorial eitleacy cff anti- CS1 monodonal antibody dotuzumab (HuLuc63) and bortezomib against multiple myeloma [ J ]. Mol Cancer Ther,2009 ;8 (9) =2616-2624.
9Morgan G. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies[J] Blood Rev, 2010;24(Suppl 1 ) :S27-S32.
10Tai Y T, Anderson K C. Antibody-based therapies in multipie myelo- ma[J]. Bone Marrow Res,2011 ;11:1-14.
3Czapiewski P,Szmuda T,Dzier;anowski J,et al. Pseudo-stroke mani- festation of multiple myeloma : a report of two cases with literature re- view[ J]. Folia Neuropathol,2013,51 ( 1 ) :87 - 91.
4Mistry PK, Taddei T, Vom Dahl S, et al. Gaucher disease and malig- nancy:a model fr cancer pathogenesis in an inborn error of metabo- lism[J]. Crit RevOncog,2013,18(3):235-246.
5Jeong TD, Kim SY,Jang S,et al. Diagnostic sensitivity of a panel of tests to detect monoclonal protein in Korean multiple myeloma pa- tients[J]. Clin Chem LabMed,2013,Jl(8):e187-e189.
6Cea M,Cagnetta A,Gobbi M,et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors [ J ]. Curr Pharm Des,2013,19(4) :734 -744.
7Osborne TR,Ramsenthaler C, Siegert RJ, et al. What issues matter most to people with multiple myeloma and how well are we measur- ing them? A systematic review of quality of life tools[J]. Eur J Haematol,2012,89 (6) :437 - 457.
8Li J, Cone JE, Kahn AR, et al. Association between World Trade Center exposure and excess cancer risk [ J]. JAMA, 2012, 308 (23) :2479 - 2488.
9Murng SH, Follows L,Whitfield P,et al. Defining the impact of in- dividual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma[ J]. Clin Exp Immunol, 2013,171(2) :201 -209.
10Geigy C,Riond B, Bley CR,et al. Multiple myeloma in a dog with multiple concurrent infectious diseases and persistent polyclonal gammopathy [ J ]. Vet Clin Patho1,2013,42 ( 1 ) :47 - 54.
